Neoadjuvant therapies for clear cell renal cell carcinoma: review of current evidence and future applications - Takeaways - MDSpire

Current Evidence and Future Directions of Neoadjuvant Treatments for Clear Cell Renal Cell Carcinoma

  • By

  • Thomas McMaster

  • Niall McVeigh

  • David C. Chen

  • Abdullah Al-Khanaty

  • Kieran Sandhu

  • Jonathon Carll

  • Dixon T. Woon

  • Declan G. Murphy

  • Nathan Lawrentschuck

  • Lewis Au

  • Muhammad Ali

  • Shankar Siva

  • Marlon Perera

  • July 17, 2026

Share

  • 1

    Renal cell carcinoma (RCC) represents about 90% of primary renal malignancies, with clear cell renal cell carcinoma (ccRCC) being the most common subtype.

  • 2

    Approximately 30% of RCC patients are diagnosed with locally advanced or metastatic disease despite improvements in early detection.

  • 3

    Neoadjuvant therapy may enhance surgical outcomes by inducing tumor cytoreduction and facilitating easier resection of advanced tumors.

  • 4

    Targeted therapies and immunotherapy can modulate the tumor microenvironment, promoting a pro-inflammatory immune response.

  • 5

    Standardized assessment methods for pathological response in RCC are being developed to improve interpretation of treatment efficacy.

Original Source(s)

Related Content